目的:通过酶联免疫吸附试验检测非霍奇金淋巴瘤(NHL)患者在初诊化疗前及2周期化疗后血浆GM-CSF及G-CSF的浓度,探讨其浓度检测的临床意义。方法:首次确诊NHL患者标本29例,同时设20例健康人为对照组,分别检测初诊化疗前、化疗2周期后及对照组血浆GM-CSF及G-CSF浓度。进行疗效评估及相关分析。结果:NHL患者初诊化疗前血浆GM-CSF及G-CSF浓度明显高于对照组,差异有统计学意义(P<0.01);化疗2周期后GM-CSF及G-CSF水平较初诊化疗前下降(P<0.05);化疗有效组GM-CSF及G-CSF较初诊时下降,差异有统计学意义(P<0.05),而无反应组GM-CSF及G-CSF较治疗前的变化无统计学意义(P>0.05);结论:GM-CSF及G-CSF在初诊NHL患者血浆中的浓度明显增高,治疗有效后2项指标均明显下降,可作为一项新的肿瘤标记物。 OBJECTIVE: To detect the concentrations of plasma GM-CSF and G-CSF in patients with non-Hodgkin’s lymphoma (NHL) before and after 2 cycles of chemotherapy by enzyme-linked immunosorbent assay (ELISA). Methods: 29 cases of NHL patients were diagnosed for the first time, and 20 healthy people were selected as the control group. The plasma concentrations of GM-CSF and G-CSF before and after the first two cycles of chemotherapy and the control group were detected. Efficacy evaluation and related analysis. Results: The plasma concentrations of GM-CSF and G-CSF in the newly diagnosed NHL patients were significantly higher than those in the control group (P <0.01). The levels of GM-CSF and G-CSF in the two cycles after chemotherapy were lower than those before the initial chemotherapy (P <0.05). The GM-CSF and G-CSF in the chemotherapy-effective group were significantly lower than those in the initial treatment group (P <0.05), but there was no statistical difference in the GM-CSF and G-CSF (P0.05) .Conclusion: The concentrations of GM-CSF and G-CSF in newly diagnosed NHL patients were significantly higher than those before treatment, and the two indicators were significantly decreased after treatment, which could be used as a new tumor marker.